Skip Navigation


Annals of Oncology Advance Access originally published online on January 11, 2007
Annals of Oncology 2007 18(4):672-678; doi:10.1093/annonc/mdl468
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/4/672    most recent
mdl468v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tsai, H.
Right arrow Articles by Mauch, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsai, H.
Right arrow Articles by Mauch, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

hematologic malignancies

Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma

HK Tsai1, S Li2, AK Ng3, B Silver3, MA Stevenson4 and PM Mauch3,*

1 Harvard Radiation Oncology Program, Boston, MA
2 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
3 Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA
4 Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

* Correspondence to: Dr P. M. Mauch, 75 Francis Street, Boston, MA 02115, USA. Tel: +1-617-732-6310; Fax: +1-617-732-7347; E-mail: pmauch{at}Iroc.harvard.edu

Background: Few large studies exist on the outcome of patients treated for stage I/II mucosa-associated lymphoid tissue (MALT) lymphoma.

Patients and methods: We retrospectively reviewed the records of 77 patients consecutively treated for stage I (n = 66) or II (n = 11) MALT lymphoma at our institution. Progression-free survival (PFS), freedom from treatment failure (FFTF), and overall survival (OS) were calculated using the Kaplan–Meier method.

Results: The median follow-up time was 61 months (range 2–177 months). Fifty-two patients (68%) received local radiation therapy (RT) alone, 17 (22%) had surgery followed by adjuvant RT, five (6%) had surgery alone, two (3%) had surgery and chemotherapy, and one patient had chemotherapy alone. The median RT dose was 30 Gy (range 18–40 Gy). The 5-year PFS, FFTF, and OS rates were 76%, 78%, and 91%, respectively. The 5-year PFS (79% versus 50%; P = 0.002) and FFTF (81% versus 50%; P = 0.0004) rates were higher for patients who received RT as compared with patients who did not.

Conclusions: The prognosis following treatment of stage I/II MALT lymphoma is excellent. RT improves PFS and FFTF and has an important role in the curative treatment of patients with localized disease.

Key words: chemotherapy, MALT lymphoma, outcome, radiotherapy, surgery

Received for publication August 23, 2006. Revision received November 14, 2006. Accepted for publication November 15, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.